<?xml version="1.0" encoding="UTF-8"?>
<p>At present, implementation of ATC therapy awaits a randomized phase 3 trial, which will start this year as part of the Horizon 2020 project TRACE (EudraCT number 2018-000853-29). Other developments include US Food and Drug Administration approval for prophylactic use of letermovir, a nontoxic oral drug active against CMV [
 <xref rid="CIT0021" ref-type="bibr">21</xref>]. A possible drawback may be development of resistance due to a low genetic barrier [
 <xref rid="CIT0022" ref-type="bibr">22</xref>]. Several studies evaluated monitoring of CMV-specific immunity [
 <xref rid="CIT0023" ref-type="bibr">23</xref>, 
 <xref rid="CIT0024" ref-type="bibr">24</xref>]. Finally, novel strategies to prevent GVHD without immunosuppression are under investigation.
</p>
